Professor Ahmed is a Professor of Gynaecological Oncology at the Nuffield Department of Women’s & Reproductive Health,  University of Oxford and the Director of the Ovarian Cancer Cell Lab at the Weatherall Institute of Molecular Medicine. Ahmed is an Honorary Consultant Gynaecological Oncology Surgeon at the Oxford University Hospitals NHS Trust and a Fellow by resolution at St Hugh’s College, University of Oxford. Ahmed discovered that TP53 mutations are ubiquitous in high grade serous ovarian cancer and introduced a new classification of serous ovarian cancer, “the Oxford classic”. Ahmed’s lab developed novel sequencing and analysis methods for studying mutational processes in cancer.  His work identified pathways to overcome chemotherapy resistance and identified novel targets for therapy. Ahmed won several prestigious national and international fellowships, prizes and awards. He holds an MBBCH from Ain Shams University in Cairo, a PhD from the University of Cambridge. He received postdoctoral training at the CRUK Cambridge Institute  and the MD Anderson Cancer Centre, University of Texas.

Professor Cerundolo (Enzo) was a Professor of Immunology at the University of Oxford and the Director of the MRC Human Immunology Unit at the Weatherall Institute of Molecular Medicine, University of Oxford. He was also a Fellow of Merton College. Enzo was a Fellow of the Royal Society and a Fellow of the Academy of Medical Sciences. Enzo made some seminal discoveries in processing and presentation of cancer and viral antigens in cells. He was also known for his contributions in understanding the biology of invariant NKT cells. Enzo discovered how the TAP genes are involved in peptide presentation to MHC Class I molecules. Enzo obtained his medical degree in the University of Padua and completed a higher degree in the Institute of Oncology, University of Padua. Enzo completed his postdoctoral research at the Weatherall Institute of Molecular Medicine. Enzo’s work with Ahmed established the foundation of Singula Bio before he sadly died in January 2020.

Professor McVeigh is an Associate Professor at the Nuffield Department of Women’s & Reproductive Health, University of Oxford. Enda is a subspecialist in Reproductive Medicine and Surgery. His research focuses on Reproductive Medicine, Endometriosis and Ovarian tissue cryopreservation. Enda was Medical Director and Lead Consultant in the Oxford Fertility Unit from 1999 until 2012. In 2011 he initiated and was one of the Founding Partners of an IVF clinic network (Reproductive Partnership) which is now the largest in the UK. Enda obtained his undergraduate degree from Queen’s University Belfast. After obtained his MRCOG he completed his Subspecialist training in Reproductive Medicine in Oxford. Enda established the Endometriosis surgical service in Oxford that eventually became a national referral centre. He was appointed as an Associate Professor in 2014.

Dr Richard Auburn is a Senior Licencing and Ventures Manager at Oxford University Innovation: the technology transfer company of the University of Oxford. Oxford University Innovation maximises the impact of the University of Oxford’s research through licensing and forming new companies.

Richard has a B.Sc.(Hon) in Microbiology and Genetics from the University of Aberdeen and a PhD in Genetics from the University of Cambridge. Before joining Oxford University Innovation, Richard’s work spanned establishing an academic cost-recovery genomics facility (Cambridge), academic research in genome structure (papers in Nature and Science), applications scientist (throughout Europe) and developing commercial molecular diagnostic assays (genetic assays). These projects were multinational collaborations that included developing and implementing genetic, molecular, automation and bioinformatics solutions. The commercial projects simultaneously involved obtaining key opinion leader input, establishing quality management systems, and supervising/supporting external partners

John Bateson is Managing Director of International Investment and Underwriting (“IIU”), which is a private equity investment company owned by Dermot Desmond, one of Ireland’s most successful entrepreneurs and investors.  John was awarded a Bachelor in Business Studies degree from Trinity College Dublin in 1985 and subsequently joined KPMG in Dublin where he qualified as a chartered accountant.  John left KPMG in 1989 to join NCB Group, then Ireland’s largest independent stockbroker, where he was a member of the corporate finance advisory team.  John joined IIU on its establishment in 1995 and, as a senior investment executive since its inception, and now Managing Director, he has been intimately involved in the creation of the current portfolio of investments.  John has over 20 years’ experience of active participation at Boardroom level across a wide range of sectors and including four publicly quoted companies.  He is a fellow of the Institute of Chartered Accountants in Ireland and a member of the Institute of Directors.

James is currently CEO of Betagenon AB, a Swedish clinical stage biotech.  He has held several senior Commercial, R&D and Business Development roles at AstraZeneca, including VP Global Marketing CV Therapy Area, VP Global Product Development for CRESTOR/rosuvastatin and VP Search & Evaluation for the CV/Metabolism/Renal Therapy Area.  He has previously worked in the Pharma/Biotech practice at McKinsey & Co.  He has a D.Phil in Cell Physiology and BM BCh (Clinical Medicine) from Oxford University, where he was a Rhodes Scholar.  He completed BM BCh Part 1 (Preclinical Medicine) at University College Cork.

Lili is an experienced immunologist with expertise in cancer immunotherapy and infectious disease. She is a Principal Scientist in translational immunology at Singula Bio and is responsible for building and implementing the company’s immunology pipelines. Prior to joining Singula bio, Lili worked at Adaptimmune Therapeutics Plc using genetic engineering, in-vitro reprogramming and combination therapies to improve adoptive T cell immunotherapy. As an academic, Lili spent 10 years at the University of Oxford, where her research, focused on T cell responses to infectious diseases ranging from fundamental research to clinical studies. She completed her D.Phil at the University of Oxford within the division of Clinical Medicine where her research focused on T cell mediated protection of the general population against seasonal and pandemic influenza.

Amro is an experienced cell biologist who has a worked in both conventional oncology and immune-oncology settings.  He is a Principal Scientist in cancer immunology at Singula Bio, responsible for developing 3D primary tumour organoid models.  Prior to joining Singula Bio, Amro held positions at a number of biotech companies spanning multiple functional areas including target validation, pipeline testing, preclinical research and clinical operations.  He has a particular interest in using primary cancer cells as a model for preclinical testing, his passion being deriving cultures of cancer cells from fresh samples and then finding ways to kill them.  Amro holds an MSc in Biomedicine from Lancaster University and a PhD in Oncology from the University of Liverpool but his most important title by far, is Dad.

Aws Al-deka is a Research Assistant in Immunotherapy at Singula Bio. Aws is responsible for conducting day-to-day research activities and providing assistant to Singula Bio’s Scientists. Aws has recently graduated with a master’s degree in Oncology from the University of Manchester, where he achieved a Distinction and was awarded the Best Student Award of 2020 for obtaining the highest marks. His MRes research project focused on the role of combining radiotherapy and immunotherapy for the treatment of solid tumours. He previously did a bachelor’s degree in Biomedical Science at Keele University, where he obtained First Class Honours. In recognition of the quality of his final-year thesis, which focused on the role of pH in breast cancer, he was awarded two prizes. Aws is motivated to carry on his research journey and advance his understanding of cancer further, through a PhD study in cancer immunology.